Imvax

John P. Furey leads Imvax as Chief Executive Officer and serves on the Board of Directors.

Prior to Imvax, he was Chief Operating Officer of Spark Therapeutics, where he led the successful U.S. launch of the first FDA-approved gene therapy for a genetic disease and contributed to the build-out of Spark as a fully integrated company. John previously served as Senior Vice President and Head of Global Operations at Baxalta, where he led a 14,000-employee manufacturing organization. Previously, John had led the spinout of Baxalta from Baxter Healthcare and was also the General Manager of Baxter Vaccines. For twenty years prior to joining Baxter, John held various global commercial and operations roles at Wyeth and Pfizer, having started his career with Wyeth at their Newbridge, Co. Kildare facility.

John also currently serves on the board of directors of Vaxcyte (NASDAQ: PCVX), an innovative clinical-stage vaccine company; Adaptimmune (NASDAQ: ADAP), a leader in T-cell therapy; and Sensorion (Euronext: ALSEN), a clinical-stage company developing therapies for the ear.

He earned an executive MBA from the Haub School of Business, St Joseph’s University, Philadelphia, a B.Sc. from Trinity College, Dublin, and a Diploma in Environmental Health from the Technological University, Dublin. John is originally from Dublin and now resides with his wife Linda and their children(Jack and Emma) in Bryn Mawr, PA.